Literature DB >> 10793068

p16(INK4a) gene alterations are frequent in lesions of mycosis fungoides.

I C Navas1, P L Ortiz-Romero, R Villuendas, P Martínez, C García, E Gómez, J L Rodriguez, D García, F Vanaclocha, L Iglesias, M A Piris, P Algara.   

Abstract

Mycosis fungoides is usually an indolent disease that, after a variable period of time in a stable phase, evolves into a tumoral form with aggressive behavior. The molecular events that mark this progression remain essentially unknown to date, and this prompted us to investigate the hypothetical role of p16(INK4a) silencing in mycosis fungoides progression. We analyzed the three most frequent mechanisms of inactivation of the p16(INK4a) gene (deletion, promoter hypermethylation, and mutation) in nine cases with patch/plaque and tumoral lesions of mycosis fungoides. The existence of alterations was investigated by microsatellite analysis, methylation-specific polymerase chain reaction, and direct sequencing. Alterations of the p16(INK4a) gene were found in four of nine of the plaque lesions (hypermethylation in three samples and allelic loss in one sample) and seven of nine in the tumor lesions (hypermethylation in five samples and allelic loss in three samples). No case presented point mutations. Although a higher incidence of p16(INK4a) hypermethylation was observed in the cases that failed to achieve a complete remission, the limited size of our series prompted us to evaluate this finding cautiously. The results of this study therefore showed a common genetic alteration that is found more frequently in tumoral lesions than it is in plaque lesions of mycosis fungoides. It also offers data that could suggest a relationship between p16(INK4a) hypermethylation and unfavorable clinical outcome. Broader studies are needed to confirm both relationships.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10793068      PMCID: PMC1876918          DOI: 10.1016/S0002-9440(10)65028-6

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  33 in total

Review 1.  Mycosis fungoides and Sezary syndrome.

Authors:  E Diamandidou; P R Cohen; R Kurzrock
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

2.  Infrequent expression of protein p53 in epidermotropic variants of cutaneous T-cell lymphoma.

Authors:  R F de Misa; J M Azaña; A Harto; C Bellas; A Ledo
Journal:  J Dermatol       Date:  1995-07       Impact factor: 4.005

3.  bcl-1, bcl-2, p53, c-myc, and lyt-10 analysis in cutaneous lymphomas.

Authors:  S A Garatti; E Roscetti; D Trecca; N S Fracchiolla; A Neri; E Berti
Journal:  Recent Results Cancer Res       Date:  1995

4.  Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.

Authors:  M Gonzalez-Zulueta; C M Bender; A S Yang; T Nguyen; R W Beart; J M Van Tornout; P A Jones
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

5.  Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.

Authors:  J G Herman; A Merlo; L Mao; R G Lapidus; J P Issa; N E Davidson; D Sidransky; S B Baylin
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

6.  Frequency of homozygous deletion at p16/CDKN2 in primary human tumours.

Authors:  P Cairns; T J Polascik; Y Eby; K Tokino; J Califano; A Merlo; L Mao; J Herath; R Jenkins; W Westra; J L Rutter; A Buckler; E Gabrielson; M Tockman; K R Cho; L Hedrick; G S Bova; W Isaacs; W Koch; D Schwab; D Sidransky
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

7.  Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and lymphoblastic leukaemia cell lines.

Authors:  R Siebert; C P Willers; A Schramm; A Fosså; I M Dresen; M Uppenkamp; M R Nowrousian; S Seeber; B Opalka
Journal:  Br J Haematol       Date:  1995-10       Impact factor: 6.998

8.  5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers.

Authors:  A Merlo; J G Herman; L Mao; D J Lee; E Gabrielson; P C Burger; S B Baylin; D Sidransky
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

9.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

Authors:  J G Herman; J R Graff; S Myöhänen; B D Nelkin; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

10.  Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies.

Authors:  S Ogawa; A Hangaishi; S Miyawaki; S Hirosawa; Y Miura; K Takeyama; N Kamada; S Ohtake; N Uike; C Shimazaki
Journal:  Blood       Date:  1995-08-15       Impact factor: 22.113

View more
  15 in total

1.  Comparative genome-scale analysis of gene expression profiles in T cell lymphoma cells during malignant progression using a complementary DNA microarray.

Authors:  S Li; D T Ross; M E Kadin; P O Brown; M A Wasik
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 2.  Epigenetic inactivation of tumor suppressor genes in hematologic malignancies.

Authors:  Tomohiro Kinoshita
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

Review 3.  Cutaneous T-cell lymphomas: a review of new discoveries and treatments.

Authors:  Tara Bloom; Timothy M Kuzel; Christiane Querfeld; Joan Guitart; Steven T Rosen
Journal:  Curr Treat Options Oncol       Date:  2012-03

4.  Chromosomal gains at 9q characterize enteropathy-type T-cell lymphoma.

Authors:  Andreas Zettl; German Ott; Angela Makulik; Tiemo Katzenberger; Petr Starostik; Thorsten Eichler; Bernhard Puppe; Martin Bentz; Hans Konrad Müller-Hermelink; Andreas Chott
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

5.  The effect of phototherapy on progression to tumors in patients with patch and plaque stage of mycosis fungoides.

Authors:  Joyce W Hoot; Li Wang; Terry Kho; Oleg E Akilov
Journal:  J Dermatolog Treat       Date:  2017-08-29       Impact factor: 3.359

Review 6.  Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome.

Authors:  Louise Photiou; Carrie van der Weyden; Christopher McCormack; H Miles Prince
Journal:  Curr Oncol Rep       Date:  2018-03-23       Impact factor: 5.075

7.  STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes.

Authors:  Qian Zhang; Hong Y Wang; Anders Woetmann; Puthiyaveettil N Raghunath; Niels Odum; Mariusz A Wasik
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

8.  Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.

Authors:  Jasmine Zain; Owen A O'Connor
Journal:  Invest New Drugs       Date:  2010-12-04       Impact factor: 3.850

9.  Expression of thymidine phosphorylase in lymph nodes involved with mycosis fungoides and sézary syndrome.

Authors:  Xingcao Nie; Rekha Bhat; Essel Dulaimi Al-Saleem; Eric C Vonderheid; J Steve Hou
Journal:  Adv Hematol       Date:  2011-11-14

10.  Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.

Authors:  Janet Y Li; Steven Horwitz; Alison Moskowitz; Patricia L Myskowski; Melissa Pulitzer; Christiane Querfeld
Journal:  Cancer Manag Res       Date:  2012-03-12       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.